Clinical Trial Update: Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating an allogeneic umbilical cord blood–derived dual-targeting BCMA/CD19 CAR-T therapy for relapsed/refractory multiple myeloma; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Allogeneic BCMA/CD19 CAR-T (umbilical cord blood-derived) (Allogeneic CAR-T cell therapy targeting BCMA and CD19)

Snippet

Sponsor: Xi'an No.3 Hospital | Conditions: Relapsed/Refractory Multiple Myeloma(MM) | Phase 1 | Status: RECRUITING